Srinivas Viswanathan
@srviswanathan
Followers
2K
Following
5K
Media
54
Statuses
1K
Physician-scientist | GU oncologist @DanaFarber @Harvardmed. Cancer genomics, functional genetics, RNA | Prostate Cancer; translocation RCC. Opinions my own.
Boston, Massachusetts
Joined December 2010
Our paper on how X chromosome alterations drive sex differences in translocation renal cell carcinoma is now out in print @CellCellPress! Link to explainer thread if you missed it 👉:
The new issue is out 👉 https://t.co/uP2kI6DjtL Featuring how X chromosome genetics constrains somatic alterations and underlies cancer sex differences, the functional mapping of RAD51C variants in cancer and single-cell genomics identifying markers of neuronal vulnerability and
7
20
134
Where do cancers start? In the liver, not all cells are the same. The liver is divided into 3 “zones,” and each specializes in different metabolic tasks. We show in @Science that where a mutation occurs in a liver lobule can determine a cell’s fate. https://t.co/3YTc77gZcd (1/9)
22
135
497
Cool new preprint from @pbachi lab! A detailed single-cell molecular portrait of MRD progression post-stem cell transplant for MDS. See thread 👇
Thrilled to share our 1st preprint (!) on @biorxiv “Molecular and cellular dynamics of measurable residual disease (#MRD) progression in myelodysplastic syndromes (MDS).” Led by the indefatigable Yu-Hsiang Chen in the lab ( https://t.co/l8hxICNpJg). 👉👉 https://t.co/1rFRt1qFws
0
0
3
These will all take time to wind their way through the publication process (♾) , but we hope sharing now sparks ideas & collabs. Lots of future directions across cancer contexts - pls reach out if interested! #OpenScience #CancerResearch [6/6]
0
0
12
#5 Led by #DharmaThapa: Phenotypic screen to identify inhibitors of TFE3 fusion activity in #translocationRCC. Early steps toward targeting the driver fusion. https://t.co/XvaMGU9XsY [5/6] #DrugDiscovery #CancerBiology
biorxiv.org
Translocation renal cell carcinoma (tRCC) is an aggressive kidney cancer driven by gene fusions of the TFE3 transcription factor. TFE3 is essential in tRCC but dispensable in normal cells, presenting...
1
1
11
#4 Led by @SimonGarinet @KarlSemaan w/ @SylvanBacaLab #MattFreedman @drchoueiri: plasma cell-free ChIP for monitoring of #translocationRCC —well-suited application of this platform in a mutationally-quiet tumor #LiquidBiopsy #Epigenomics
https://t.co/KuC61n3ukM [4/6]
biorxiv.org
TFE3 translocation renal cell carcinoma (tRCC), an aggressive kidney cancer driven by TFE3 gene fusions, is frequently misdiagnosed owing to morphologic overlap with other kidney cancer subtypes....
1
1
13
#3 Led by @Shikha_Gupta68 w/ @drchoueiri: a potential new combo in #translocationRCC—CDK4/6i + mTORC1-selective inhibitor. Promising preclinical data. #CancerTherapy #TargetedTherapy
https://t.co/7C5aXHGheQ [3/6]
biorxiv.org
Purpose Translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of kidney cancer driven by an oncogenic fusion involving a transcription factor in the MiT/TFE gene family, most...
1
0
12
#2 Led by @labratsprats w/ @drchoueiri @vanallenlab @LabSignoretti : snRNAseq of tRCC (17 tumors, ~90K cells!) vs ccRCC. They’re molecularly distinct - w/ clinical implications. #KidneyCancer #SingleCell. Link to 🧵: https://t.co/rRsTh3bhNS
https://t.co/HbFA9VSxu9 [2/6]
biorxiv.org
Renal cell carcinomas comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete...
Late 🧵, but excited to share the first part of my postdoc work under @srviswanathan ’s mentorship! 🔗 https://t.co/tNEeDNbXSF Our work focuses on translocation RCC (tRCC) — a rare & aggressive kidney cancer that remains a black box despite progress in clear-cell RCC.
1
0
12
#1 Led by @Sadagopan_A @jiaoli43141960 #bingchenli: Framework to infer tumor dependencies from transcriptional profiles & nominate patient-specific targets; esp useful in rare cancers lacking models. #RareCancer. Link to 🧵: https://t.co/G7NcOuP7eM
https://t.co/rJ4VaDvqnk [1/6]
biorxiv.org
Functional genetic screens have uncovered dependencies in many cancers, but experimentally screened models for most cancers are far outnumbered by molecularly-profiled tumors, particularly for rare...
Excited to share my project w/@srviswanathan on virtual CRISPR screening -- predicting cancer dependencies from RNA sequencing alone. On unseen rare tumors, nearly every predicted dependency validated experimentally! Creating a framework to rapidly go from patient → treatment
2
0
12
We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]
5
19
54
If you have been diagnosed with #TranslocationRenalCellCarcinoma, please consider sharing your story to help advance research and understanding of this rare disease. 🔗 https://t.co/EJWI2LbYj5 | Learn more in the video below! #RareCancerResearch
tRCC, or translocation renal cell carcinoma, is a rare subtype of kidney cancer. Learn more about the tRCC project and how patients can help accelerate research on this disease. @count_me_in @broadinstitute @srviswanathan Read more: https://t.co/BY0F1p7gzY
0
1
5
Thrilled to share our new work published in Nature ( https://t.co/6KIgZiDhMN). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC. https://t.co/8UyaKWbecQ
nature.com
Nature - Dual cyclin A/B RxL inhibitors selectively kill small cell lung cancer cells and other cancer cells with high E2F activity.
9
24
136
Congratulations @DrPrateekKhanna and excited for you as you embark on this new phase!! 🩺-🔬
Welcoming @DrPrateekKhanna as new faculty to the @DanaFarber_GU @DanaFarber —Prateek had excellent lab and clinical training in GU cancers (@srviswanathan, Rupal Bhatt @BIDMChealth)! He just came back from #VailWorkshop @ASCO @AACR and he is ready to take over the world!
0
0
15
See 👇 : opportunity to do exciting science in a great lab w/ a kind mentor!
Come join us @MSKCancerCenter! You’ll work with @EdReznik and I on really cool science Please help spread the word @DrChoueiri @BraunMDPhD @srviswanathan @VanAllenLab @OncoAlert @Chrislabaki1 @ReneeSaliby @eddy_saad
0
1
1
1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out @JCO_ASCO !!! Incredibly thankful to my mentors @BraunMDPhD @DrChoueiri @VanAllenLab and all co-authors @DanaFarber @BIDMC_IM @Yale @BrighamWomens Link:
ascopubs.org
PURPOSEWhile immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC...
5
31
102
Congrats to the @theNCI Team on this landmark paper in HLRCC! It sets the SOC in this rare kidney cancer variant. @NEJM @NCICCR_SurgOnc @nciccr_gmb
nejm.org
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papil...
2
34
101
Here's our latest, led by superstars @JoYatesResearch & Dr. Camille Mathey-Andrews, jointly with @val_boeva and many more @DanaFarberNews @broadinstitute We studied primary & lethal esophageal cancer using multi[RNA, ATAC, spatial]-omics, see Josephine's tweets below for more!👇
Thrilled to share our new paper out today in Cell Reports Medicine! @VanAllenLab @val_boeva We map cell states & neighborhoods across clinical stages of esophageal adenocarcinoma (EAC) using single-cell, epigenomic & spatial data.🔗 https://t.co/e0fzzHCfmi (1/9)
2
16
68
📢 #ASCO25: AREN1721 trial in translocation RCC (tRCC) closed early due to poor accrual (n=13), but key signals emerged: 🧪 Nivolumab+axitinib➡️ PR in 33%, median PFS ↑ from 1.8 → 10.5 mo (p=0.0004) 💊 Nivo alone showed no activity ⚠️ No unexpected toxicities 🚨 Trial
1
5
18
🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4521: Dr #JAmesGeller presenting Nivo/Axitinib vs Nivo in pts with translocation RCC #AREN1721 🩺Clinical implications: - Nivo/Axitinib (n=6) showed early efficacy ORR 33% and mPFS 10mo - #TranslocationRCC remains a disease of unmet
0
8
13
1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest @ImmunityCP study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉 https://t.co/3O9JiiG7sH
#MsaouelLab
15
38
95
A new study from Damon Runyon Innovator @srviswanathan takes a closer look at the behavior of the “inactive” X chromosome—and offers a potential explanation for sex-based differences in cancer. Read more: https://t.co/SuFqf7z2Ba
0
3
8